Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Residual cariogenic bacteria refer to the diverse community of acid-producing microorganisms, primarily Streptococcus mutans and Lactobacillus species, that remain within the dentinal tubules or the floor of a cavity after the removal of carious tissue (Takahashi & Nyvad, 2011; Conrads et al., 2019). These bacteria possess the ability to survive in low-oxygen, nutrient-poor environments by metabolizing residual carbohydrates into organic acids, which further demineralizes the tooth structure (Takahashi & Nyvad, 2011). Their presence is a significant clinical concern as they can lead to secondary caries, restoration failure, and the progression of infection into the dental pulp (Schwendicke et al., 2016; Maltz et al., 2013). Therapeutic strategies involve the use of cavity disinfectants, such as chlorhexidine or silver diamine fluoride, which aim to eradicate these pathogens or inhibit their metabolic activity (Mei et al., 2013). Modern restorative materials may also incorporate antimicrobial agents to provide long-term suppression of these residual populations (Mei et al., 2013). Understanding the composition and survival mechanisms of this microbiota is essential for the success of minimally invasive dentistry and the preservation of tooth vitality (Schwendicke et al., 2016).
Drugs targeting these bacteria typically act through the disruption of bacterial cell membranes, inhibition of essential metabolic enzymes such as enolase, and interference with bacterial adhesion and biofilm maturation.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Residual cariogenic bacteria.